Afatinib, a second‐generation EGFR‐TKI, is the preferred first‐line option for NSCLC with certain uncommon mutations [13], and its efficacy has been evaluated in two retrospective analyses [10, 16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.